- Home
- GALT vs WHWK Comparison
GALT vs WHWK Comparison
Compare GALT & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | WHWK |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 179.8M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | WHWK |
|---|---|---|
| Price | $2.36 | $4.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $8.50 | $7.50 |
| AVG Volume (30 Days) | ★ 337.9K | 229.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $1.39 |
| 52 Week High | $7.13 | $4.40 |
Technical Indicators
Market Signals| Indicator | GALT | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 67.72 |
| Support Level | $2.13 | $1.84 |
| Resistance Level | $3.32 | $4.40 |
| Average True Range (ATR) | 0.20 | 0.28 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 30.47 | 99.07 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.